CELSCI Corporation

CELSCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases The companys lead investigational immunotherapy is Multikine which is under phase III clinical trial for the treatment of head and neck cancer Its Ligand Epitope Antigen Presentation System LEAPS a preclinical patented Tcell modulation process that stimulates the human immune system to fight bacterial viral and parasitic infections as well as autoimmune diseases allergies transplantation rejections and cancer The company also develops LEAPSH1N1DC CEL2000 and CEL4000 are product candidates for the treatment of rheumatoid arthritis and LEAPS COV19 a product candidate to treat COVID19 coronavirus CELSCI Corporation has a collaboration agreement with the University of Georgias Center for Vaccines and Immunology to develop LEAPS COVID19 immunotherapy The company was incorporated in 1983 and is headquartered in Vienna Virginia